| pubmed-article:2567440 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2567440 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:2567440 | lifeskim:mentions | umls-concept:C0022322 | lld:lifeskim |
| pubmed-article:2567440 | lifeskim:mentions | umls-concept:C0029001 | lld:lifeskim |
| pubmed-article:2567440 | pubmed:issue | 8652 | lld:pubmed |
| pubmed-article:2567440 | pubmed:dateCreated | 1989-7-21 | lld:pubmed |
| pubmed-article:2567440 | pubmed:abstractText | In a prospective study to determine the tolerance for and safety of ivermectin therapy for onchocerciasis in a hyperendemic area in Sierra Leone, 28 (32%) of 87 patients had adverse reactions that required treatment with acetylsalicylic acid and antihistamines, but none of the observed adverse reactions were considered life-threatening. A significant relation was found between the frequency and severity of side-effects and the degree of parasite infestation, as quantified by the skin-snip counts. Free administration of ivermectin to severely infected onchocerciasis patients is not recommended without some form of medical supervision. | lld:pubmed |
| pubmed-article:2567440 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2567440 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2567440 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:2567440 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2567440 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2567440 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:2567440 | pubmed:issn | 0140-6736 | lld:pubmed |
| pubmed-article:2567440 | pubmed:author | pubmed-author:WilsonW RWR | lld:pubmed |
| pubmed-article:2567440 | pubmed:author | pubmed-author:van der... | lld:pubmed |
| pubmed-article:2567440 | pubmed:author | pubmed-author:StilmaJ SJS | lld:pubmed |
| pubmed-article:2567440 | pubmed:author | pubmed-author:RothovaAA | lld:pubmed |
| pubmed-article:2567440 | pubmed:author | pubmed-author:BarbeR FRF | lld:pubmed |
| pubmed-article:2567440 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2567440 | pubmed:day | 24 | lld:pubmed |
| pubmed-article:2567440 | pubmed:volume | 1 | lld:pubmed |
| pubmed-article:2567440 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2567440 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2567440 | pubmed:pagination | 1439-41 | lld:pubmed |
| pubmed-article:2567440 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2567440 | pubmed:meshHeading | pubmed-meshheading:2567440-... | lld:pubmed |
| pubmed-article:2567440 | pubmed:meshHeading | pubmed-meshheading:2567440-... | lld:pubmed |
| pubmed-article:2567440 | pubmed:meshHeading | pubmed-meshheading:2567440-... | lld:pubmed |
| pubmed-article:2567440 | pubmed:meshHeading | pubmed-meshheading:2567440-... | lld:pubmed |
| pubmed-article:2567440 | pubmed:meshHeading | pubmed-meshheading:2567440-... | lld:pubmed |
| pubmed-article:2567440 | pubmed:meshHeading | pubmed-meshheading:2567440-... | lld:pubmed |
| pubmed-article:2567440 | pubmed:meshHeading | pubmed-meshheading:2567440-... | lld:pubmed |
| pubmed-article:2567440 | pubmed:meshHeading | pubmed-meshheading:2567440-... | lld:pubmed |
| pubmed-article:2567440 | pubmed:meshHeading | pubmed-meshheading:2567440-... | lld:pubmed |
| pubmed-article:2567440 | pubmed:meshHeading | pubmed-meshheading:2567440-... | lld:pubmed |
| pubmed-article:2567440 | pubmed:meshHeading | pubmed-meshheading:2567440-... | lld:pubmed |
| pubmed-article:2567440 | pubmed:meshHeading | pubmed-meshheading:2567440-... | lld:pubmed |
| pubmed-article:2567440 | pubmed:meshHeading | pubmed-meshheading:2567440-... | lld:pubmed |
| pubmed-article:2567440 | pubmed:meshHeading | pubmed-meshheading:2567440-... | lld:pubmed |
| pubmed-article:2567440 | pubmed:meshHeading | pubmed-meshheading:2567440-... | lld:pubmed |
| pubmed-article:2567440 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2567440 | pubmed:articleTitle | Side-effects of ivermectin in treatment of onchocerciasis. | lld:pubmed |
| pubmed-article:2567440 | pubmed:affiliation | Department of Ophthalmo-immunology, Netherlands Ophthalmic Research Institute, Amsterdam. | lld:pubmed |
| pubmed-article:2567440 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2567440 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:2567440 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2567440 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2567440 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2567440 | lld:pubmed |
